Precision BioSciences, Inc. DTIL
Precision BioSciences, Inc. (Nasdaq: DTIL) is an infectious disease drug developer. Its lead program, PBGENE-HBV, is in Phase 1 for chronic hepatitis B. Its next catalyst on record is PBGENE-HBV: PBGENE-HBV Phase 2 ELIMINATE-B2 study initiation expected in Q1 2027. (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PBGENE-HBV — PBGENE-HBV Phase 2 ELIMINATE-B2 study initiation expected in Q1 2027. (Q1 2027). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PBGENE-HBV | chronic hepatitis B | gene therapy | Phase 1 |
| PBGENE-DMD | Duchenne muscular dystrophy | gene therapy | Phase 1 |
| ECUR-506 (partnered with iECURE) | neonatal-onset ornithine transcarbamylase deficiency | gene therapy | Phase 1 |
| azer-cel (partnered with TG Therapeutics) | progressive multiple sclerosis | cell therapy | Phase 1 |
| azer-cel (partnered with Imugene) | diffuse large B-cell lymphoma | cell therapy | Phase 1 |
Recent results and decisions
- Nov 5, 2026met PBGENE-HBV achieved undetectable pgRNA in 100% of evaluable patients at 0.4 mg/kg dose in Phase 1 ELIMINATE-B study.
PBGENE-HBV achieved pgRNA loss to undetectable in 100% of evaluable patients at expected go-forward dose of 0.4 mg/kg; Durable and ongoing pgRNA loss in 100% of patients with ≥6 months of follow-up
Filing - Nov 5, 2026positive First PBGENE-DMD patient completed 8-week observation with no serious adverse events or safety concerns.
No serious adverse events, no adverse events of special interest (including no TMA, myocarditis, or acute liver injury) DSMB has reviewed patient 1 data through week 8
Filing - Sep 30, 2026started First patient dosed with PBGENE-DMD at Arkansas Children's Hospital in the Phase 1/2 FUNCTION-DMD study.
The third quarter also marked an important milestone for Precision BioSciences and more importantly for the children who live with Duchenne muscular dystrophy (DMD). Our team alongside our investigators commenced dosing of the first patient in the FUNCTION-DMD trial.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 infectious disease companies
- Assembly Biosciences, Inc. ASMB
- Tevogen Inc. TVGN
- Nanoviricides, Inc. NNVC
- Cocrystal Pharma, Inc. COCP
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.